{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:15:40Z","timestamp":1789503340715,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015696","name":"NATIONAL HEALTH INSURANCE SERVICE ILSANHOSPITAL","doi-asserted-by":"publisher","award":["NHIMC2021PR002"],"award-info":[{"award-number":["NHIMC2021PR002"]}],"id":[{"id":"10.13039\/501100015696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejca.2023.05.020","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T04:03:12Z","timestamp":1685592192000},"page":"112932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea"],"prefix":"10.1016","volume":"189","author":[{"given":"Byung Kyu","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung-Ho","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Ju","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Kyu","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2023.05.020_bib1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"issue":"10242","key":"10.1016\/j.ejca.2023.05.020_bib2","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2023.05.020_bib3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2023.05.020_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CLEP.S20611","article-title":"Pancreatic cancer survival in central and northern Denmark from 1998 through 2009: a population-based cohort study","volume":"3","author":"Cronin-Fenton","year":"2011","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ejca.2023.05.020_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2019.11.002","article-title":"Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma","volume":"125","author":"Latenstein","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41571-018-0112-1","article-title":"Optimizing the outcomes of pancreatic cancer surgery","volume":"16","author":"Strobel","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2023.05.020_bib7","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1016\/S1470-2045(13)70172-4","article-title":"Improvement of surgical results for pancreatic cancer","volume":"14","author":"Hartwig","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2023.05.020_bib8","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2023.05.020_bib9","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ejca.2023.05.020_bib10","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2023.05.020_bib11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ejca.2009.01.033","article-title":"Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland","volume":"45","author":"Sharp","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.020_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jjco\/hyaa183","article-title":"Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan","volume":"51","author":"Suzuki","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.020_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.2009.25.8608","article-title":"Generalizing the results of cancer clinical trials","volume":"28","author":"Meyer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.020_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4143\/crt.2021.044","article-title":"Validation of cancer diagnosis based on the national health insurance service database versus the national cancer registry database in Korea","volume":"54","author":"Yang","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s12885-021-08082-2","article-title":"Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.05.020_bib16","series-title":"Age standardization of rates: a new WHO standard","author":"Ahmad","year":"2001"},{"key":"10.1016\/j.ejca.2023.05.020_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/sim.1597","article-title":"Regression models for relative survival","volume":"23","author":"Dickman","year":"2004","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.ejca.2023.05.020_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/MPA.0000000000001833","article-title":"Patterns of palliative chemotherapy and survival in patients with pancreatic cancer focusing on age: a nationwide real-world Danish registry study","volume":"50","author":"Rasmussen","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3747\/co.27.5211","article-title":"Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study","volume":"27","author":"Shakeel","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2023.05.020_bib20","unstructured":"Korea Central Cancer Registry, National Cancer CenterAnnual report of cancer statistics in Korea in 2019. Ministry of Health and Welfare 2021."},{"issue":"5","key":"10.1016\/j.ejca.2023.05.020_bib21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.cgh.2020.02.054","article-title":"Burden of pancreatic cancer: from epidemiology to practice","volume":"19","author":"Khalaf","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2023.05.020_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canep.2018.04.011","article-title":"Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates","volume":"55","author":"Minicozzi","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"10.1016\/j.ejca.2023.05.020_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.pan.2020.01.012","article-title":"Pancreatic cancer incidence and survival and the role of specialist centres in resection rates in England, 2000 to 2014: a population-based study","volume":"20","author":"Exarchakou","year":"2020","journal-title":"Pancreatology"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib24","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","article-title":"Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations","volume":"68","author":"Huang","year":"2019","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.ejca.2023.05.020_bib25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ejca.2023.05.020_bib26","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.ejca.2023.05.020_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejca.2023.05.020_bib28","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/cam4.921","article-title":"The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis","volume":"5","author":"Bakens","year":"2016","journal-title":"Cancer Med"},{"issue":"3\u20134","key":"10.1016\/j.ejca.2023.05.020_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000510343","article-title":"Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence","volume":"106","author":"M\u00fcller","year":"2021","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.ejca.2023.05.020_bib30","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with Folfirinox results in resectability in 60% of the patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.020_bib31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","article-title":"Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection","volume":"270","author":"Gemenetzis","year":"2019","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejca.2023.05.020_bib32","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","article-title":"Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials","volume":"160","author":"van Dam","year":"2022","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2023.05.020_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1634\/theoncologist.2016-0447","article-title":"Patterns of chemotherapy use in a U.S.-based cohort of patients with metastatic pancreatic cancer","volume":"22","author":"Abrams","year":"2017","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib34","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1038\/s41598-020-64068-3","article-title":"Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study","volume":"10","author":"Wang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.05.020_bib35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/ije\/dyp392","article-title":"Measuring cancer survival in populations: relative survival vs cancer-specific survival","volume":"39","author":"Sarfati","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.ejca.2023.05.020_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jncimonographs\/lgu024","article-title":"Cancer survival: an overview of measures, uses, and interpretation","volume":"2014","author":"Mariotto","year":"2014","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ejca.2023.05.020_bib37","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.7314\/APJCP.2012.13.11.5681","article-title":"Comparison between overall, cause-specific, and relative survival rates based on data from a population-based cancer registry","volume":"13","author":"Utada","year":"2012","journal-title":"Asian Pacific J Cancer Prev"},{"issue":"2","key":"10.1016\/j.ejca.2023.05.020_bib38","doi-asserted-by":"crossref","first-page":"dju413","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ejca.2023.05.020_bib39","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Suker","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib40","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.clon.2017.10.017","article-title":"Uptake and effectiveness of FOLFIRINOX for advanced pancreatic cancer: a population-based study","volume":"30","author":"Karim","year":"2018","journal-title":"Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.05.020_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.21873\/invivo.11471","article-title":"Improvement of treatment outcomes for metastatic pancreatic cancer: a real-world data analysis","volume":"33","author":"Sasaki","year":"2019","journal-title":"In Vivo"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923002691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:07Z","timestamp":1760733667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923002691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"alternative-id":["S0959804923002691"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.05.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.05.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112932"}}